Clinical trials
Newly Diagnosed Multiple Myeloma clinical trials
Below are recruiting newly diagnosed multiple myeloma clinical trials, each written for real people, not researchers. We’re tracking 94 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06892522RecruitingPhase 1/Phase 2
T cell therapies for multiple myeloma
This trial tests new antibody treatments for multiple myeloma, given alone or with other drugs. It aims to see if they can control the disease and what side effects might occur.
Duarte, CaliforniaAges 18 years+ - NCT05312255Recruiting
Non-drug help to improve quality of life in myeloma
This study tests non-chemotherapy supports meant to improve quality of life and immune health for people with multiple myeloma (or related conditions). Depending on the group, it may involve activities, nutrition, and/or a medication like a beta blocker.
Buffalo, New YorkAges 18 years+ - NCT05055063RecruitingPhase 1
Belantamab for high-risk smoldering myeloma safety and early benefit
This Phase 1 trial tests belantamab mafodotin, a cancer medicine, in people with high-risk smoldering multiple myeloma to see how safe it is and whether it may shrink or control the disease. Because it’s an early-stage study, you would be closely monitored and treated with one main study drug.
Houston, TexasAges 18 years+ - NCT07649525RecruitingPhase 3
Personalized myeloma treatment based on response and fitness
This trial tests whether tailoring myeloma treatment based on how well you respond to initial therapy and your overall health status can improve outcomes. You'll receive standard first-line treatment (three drugs: daratumumab, lenalidomide, and dexamethasone) and then be assigned to a personalized pathway based on your response and fitness level.
BristolAges 18 years+ - NCT00900198Recruiting
Give cancer tissue samples to help future cancer research
This study collects tissue or other cancer-related samples to help researchers better understand cancer and develop better tests or treatments. You can join if you are being evaluated for or treated for cancer, and you agree to let your samples be used for research.
Sacramento, CaliforniaAges 2 months+ - NCT06483100RecruitingPhase 2
Elranatamab after stem cell transplant for multiple myeloma
This trial tests a drug called elranatamab to keep multiple myeloma from coming back after an autologous stem cell transplant. It is for people who still have small amounts of cancer cells detectable after transplant.
St Louis, MissouriAges 18 years+ - NCT07224672RecruitingPhase 2
Study of a drug combo for newly diagnosed AL amyloidosis
This trial tests a combination of four drugs (belantamab mafodotin, cyclophosphamide, bortezomib, and dexamethasone) for people newly diagnosed with AL amyloidosis who cannot have a stem cell transplant. The goal is to see if this combination is safe and effective at stopping the abnormal proteins from damaging your organs.
Rochester, MinnesotaAges 18 years+ - NCT04513639RecruitingPhase 2/Phase 3
Checking treatment for multiple myeloma after MRD becomes negative
This study looks at whether people with newly diagnosed multiple myeloma can safely continue or adjust treatment after they reach “MRD-negative,” meaning very low signs of disease in the bone marrow. It may help reduce the chance of relapse while avoiding unnecessary treatment for some patients.
ÅlesundAges 18–75 - NCT04988555RecruitingPhase 1/Phase 2
Study of an investigational drug for high-risk acute leukemia
This Phase 1/2 study tests enzomenib (DSP-5336) in people with relapsed or hard-to-treat acute leukemia (and, in some places, certain other blood cancers). The goal is to see how the drug works and how safe it is, especially for leukemia cases with specific genetic changes (KMT2A/MLL or NPM1).
Newport Beach, CaliforniaAges 12 years+ - NCT04991103RecruitingPhase 2
Testing delaying stem cell transplant after early myeloma response
This Phase 2 study tests whether people with newly diagnosed multiple myeloma can safely delay or avoid an immediate stem cell transplant if they respond well to early treatment. It aims to see if this “response-adapted” approach can still control the disease while reducing the need for upfront transplant for some patients.
Birmingham, AlabamaAges 18 years+ - NCT05366881Recruiting
Blood test study to spot early cancer signal and cancer leftovers
This observational study checks whether a blood test (a “cfDNA” test) can detect early signs of cancer or small amounts of cancer left after treatment. It may help doctors use a simple blood sample to improve cancer detection and follow-up.
Duarte, CaliforniaAges 40 years+ - NCT05695508RecruitingPhase 2
Tested treatment for multiple myeloma after standard care
This Phase 2 study tests a study treatment in adults with multiple myeloma that needs treatment. It may help by trying to improve disease control after you’ve had (or are scheduled to have) standard therapy like chemotherapy and stem cell transplant for some people.
BerlinAges 18–70 - NCT06022939RecruitingPhase 3
Comparing chemo plus stem cell transplant to chemo alone for AL amyloidosis
This study tests whether adding a stem cell transplant to standard chemotherapy (Dara-VCD) works better than chemotherapy alone for people newly diagnosed with AL amyloidosis. It aims to find the best way to control the disease and improve outcomes.
Goodyear, ArizonaAges 18 years+ - NCT06636175RecruitingEarly Phase 1
New imaging test for blood cancers
This study tests a new imaging agent called 64Cu-LLP2A to see if it can better detect certain blood cancers like multiple myeloma and low-grade lymphomas. It aims to find tumors more clearly than standard scans, which could help your doctor plan the best care for you.
St Louis, MissouriAges 18 years+ - NCT06658834RecruitingPhase 2
Romiplostim for newly diagnosed ITP in adults
This trial tests a medicine called romiplostim (Nplate) as a first treatment for adults newly diagnosed with ITP. It aims to see if it can safely raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06697483Recruiting
Personalized maintenance therapy for multiple myeloma after stem cell transplant
This trial tests a personalized approach to maintenance therapy for people with multiple myeloma who have already had a stem cell transplant. Your treatment plan may be adjusted based on how well your cancer responds and on certain risk factors, with the goal of keeping you in remission longer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06910124RecruitingPhase 2
Testing linvoseltamab with lenalidomide for multiple myeloma
This trial tests adding a new drug, linvoseltamab, to the standard maintenance therapy lenalidomide for people with newly diagnosed multiple myeloma. The goal is to see if it can deepen responses or turn a relapse back to a negative minimal residual disease (MRD) state, where no cancer cells are detectable.
Miami, FloridaAges Any age - NCT06992128RecruitingPhase 2
Romiplostim plus steroids for newly diagnosed ITP
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07079423RecruitingPhase 2
Teclistamab for new advanced AL amyloidosis
This trial tests a new drug called teclistamab for people newly diagnosed with advanced (stage IIIB) AL amyloidosis, a condition where abnormal proteins build up and damage organs. The goal is to see if teclistamab can help control the disease.
BeijingAges 18 years+ - NCT07106684RecruitingPhase 2
Stem cell transplant with car-t and bi-specific antibody for plasma cell leukemia
This trial tests a treatment plan for newly diagnosed plasma cell leukemia that involves a stem cell transplant followed by two types of immunotherapy: CAR-T cells targeting BCMA and a bi-specific antibody targeting GPRC5D. The goal is to see if this approach can help keep the cancer in remission.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07149857RecruitingPhase 2
A study of CAR-T therapy for newly diagnosed multiple myeloma
This trial tests a one-time cell therapy called ciltacabtagene autoleucel (a CAR-T treatment) in people who have newly diagnosed multiple myeloma and are not eligible for a stem cell transplant. It aims to see if this treatment is safe and effective as an early therapy.
San Francisco, CaliforniaAges 18–80 - NCT07652879RecruitingPhase 2
KCD drug combination for newly diagnosed POEMS syndrome
This trial tests a combination of three drugs (carfilzomib, cyclophosphamide, and dexamethasone) for people newly diagnosed with POEMS syndrome. It aims to see how well this treatment helps control the disease and its symptoms.
ShanghaiAges 18–75
Hear when a new Newly Diagnosed Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for newly diagnosed multiple myeloma?
- Yes. Clin2 currently lists 94 recruiting newly diagnosed multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a newly diagnosed multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a newly diagnosed multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.